Author

Asma BOUDERSA

Observed names: A Boudersa, A. Boudersa, Asma Boudersa

Observed institution: Badji Mokhtar-Annaba University

OpenAlex ID: A5071654666

Association of TERT, OGG1, and CHRNA5 Polymorphisms and the Predisposition to Lung Cancer in Eastern Algeria

2020 · Asma Mimouni, Etienne Rouleau, et al. · Pulmonary Medicine · 8

The Median of Progression free survival in Patients with HR+/HER2− Metastatic Breast Cancer Treated with Initial Endocrine Therapy in Eastern Algeria. A prospective study.

2025 · Asma BOUDERSA, Nassima KOUADRI, et al. · Batna Journal of Medical Sciences (BJMS) · 1

PDF

Evaluation of First-Line Endocrine Therapy for HR+/HER2- Metastatic Breast Cancer: Efficacy, Tolerance and Prescribing Practices. A Prospective and Observational study

2024 · Asma BOUDERSA, Nassima KOUADRI, et al. · Batna Journal of Medical Sciences (BJMS) · 1

PDF

Epidemiology of breast cancer among men

2017 · A. Boudersa, N. Kouadri, et al. · Annals of Oncology · 1

First-Line Endocrine Therapy Effectiveness in Recurrent HR+/HER2− Metastatic Breast Cancer: A Comprehensive Retrospective Study in Eastern Algeria

2026 · Asma BOUDERSA, Nassima KOUADRI, et al. · Batna Journal of Medical Sciences (BJMS)

PDF

Complete Pathological Response and Severe Hypothyroidism under Pembrolizumab in Triple-Negative Breast Cancer: Between Triumph and Toxicity – A Case Report.

2026 · Asma BOUDERSA, Nassima KOUADRI, et al. · Batna Journal of Medical Sciences (BJMS)

PDF

Hormone Therapy in Localized Luminal Breast Cancer: Current State of Knowledge and Recommendations

2025 · Asma BOUDERSA, Nassima KOUADRI · Batna Journal of Medical Sciences (BJMS)

PDF

P280: Identifying Predictive Factors of Lymph Node Involvement in Stage I and II Luminal Breast Cancers to Optimize Neoadjuvant Chemotherapy Indication

2025 · A. Boudersa, N. Kouadri, et al. · The Breast

P168: Stage III breast cancer: clinical characteristics and evolution

2025 · N. Kouadri, L. Naoun, et al. · The Breast

P229: Impact of neoadjuvant chemotherapy on early relapses of luminal stage II breast cancer

2025 · N. Kouadri, A. Boudersa, et al. · The Breast

P223: Analysis of Pathological Complete Response (pCR) Rates Based on HER2 LowScore and HER-0 in Luminal Breast Cancer Patients after Neoadjuvant Chemotherapy, A retrospective study

2025 · A. Boudersa, N. Kouadri, et al. · The Breast

P031: Objective Response to Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study

2025 · A. Boudersa, A. Bouguettaya, et al. · The Breast

P029: The contribution of the double blockade “Pertuzumab – Trastuzumab” in neo-adjuvant situation in localized Her2 positive Breast Cancers (Algerian experience)

2025 · A. Bouguettaya, A. Boudersa, et al. · The Breast

Treatment-induced anemia in oncology, towards personalized and multimodal management.

2024 · Asma BOUDERSA, Nassima KOUADRI · Batna Journal of Medical Sciences (BJMS)

PDF

150P Pathological complete response after neoadjuvant chemotherapy in HER2-positive breast cancer, efficacy of biosimilar compared to reference trastuzumab

2023 · N. Kouadri, N.N. Belili, et al. · ESMO Open

PDF

P081 Breast cancer in young women

2023 · N. Kouadri, L. Naoun, et al. · The Breast

P129 Neoadjuvant chemotherapy in ER-positive Early Breast Cancer: predictive factors of response and outcome

2023 · N. Kouadri, A. Boudersa, et al. · The Breast

Fatigue in oncology. A marginalized symptom by oncologists, silently handicapping cancer patients!

2019 · Oncologie medicale, CHU Khelil Amrane, Béjaia – Algérie., Asma BOUDERSA, et al. · Batna Journal of Medical Sciences (BJMS)

PDF

Glioblastome récurrent inopérable : une réponse complète

2018 · Asma BOUDERSA, Hanane DJEDI · Batna Journal of Medical Sciences (BJMS)

PDF

Works count: 19

Citation count: 11

H-index: 1

I10-index: